Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
Ortega-Paz, Luis (University of Florida)
Sionis, Alessandro (Institut de Recerca Sant Pau)
Arevalos, Victor (Universidad Nacional de Asunción)
Andrea-Riba, Rut (Hospital Clínic i Provincial de Barcelona)
De Diego, Oriol (Universidad Nacional de Asunción)
Ortega, Emilio (Hospital Clínic i Provincial de Barcelona)
Dantas, Ana Paula (Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Angiolillo, Dominick J. (University of Florida)
Sabaté, Manel (Hospital Clínic i Provincial de Barcelona)
Ortiz Pérez, José Tomás (Hospital Clínic i Provincial de Barcelona)
Brugaletta, Salvatore (Hospital Clínic i Provincial de Barcelona)
Laudani, Claudio (University of Catania)
Vidal-Calés, Pablo (Hospital Clínic i Provincial de Barcelona)
Morr, Carlos Igor (Hospital Clínic i Provincial de Barcelona)
Jimenez Trinidad, Francisco Rafael (Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))

Fecha:	2025
Resumen:	Background: Myocardial fibrosis leads to ventricular dysfunction and worsened prognosis, especially after ST-segment elevation myocardial infarction (STEMI). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) offer cardiovascular benefits by reducing markers of myocardial fibrosis and fibroblast activity. However, the effects of SGLT2i on myocardial fibrosis deposition among STEMI patients undergoing primary percutaneous coronary intervention (PCI) have not yet been evaluated. Study and Design: The effect of DAPAgliflozin on myocardial fibrosis and ventricular function in patients with STEMI (DAPA-STEMI) trial is a phase III, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the effects of dapagliflozin on myocardial fibrosis and ventricular function, evaluated using cardiac magnetic resonance (CMR), in STEMI patients undergoing primary PCI. Eligible patients were 30 to 85 years old and exhibited a left ventricular ejection fraction ≤ 50%. A total of 120 patients with STEMI were expected to be randomized 1:1 to receive dapagliflozin 10 mg or placebo daily for six months. The primary endpoint is the change in the extracellular volume fraction of the remote myocardium from baseline to six months, as measured by CMR. The secondary endpoints include changes in the circulating C-terminal propeptide of type I procollagen, N-terminal propeptide of type III procollagen, and Galectin-3 from baseline to six months. The study was stopped prematurely due to slow recruitment, with 54 enrolled patients, limiting the statistical power to detect changes in the primary endpoint between groups. Conclusions: The DAPA-STEMI trial will provide insights into the impact of dapagliflozin on myocardial fibrosis and ventricular remodeling in patients with STEMI undergoing primary PCI. Clinical Trial Registration Unique Identifier: NCT06619600.
Derechos:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cardiac magnetic resonance ; Dapagliflozin ; Extracellular space ; Heart failure ; Left ; Myocardial fibrosis ; Myocardial infarction ; Randomized controlled trial ; Sodium-glucose transporter 2 inhibitors ; Ventricular function ; Ventricular remodeling
Publicado en:	Journal of Cardiovascular Development and Disease, Vol. 12, Num. 6 (June 2025) , p. 220, ISSN 2308-3425

DOI: 10.3390/jcdd12060220
PMID: 40558655

13 p, 580.5 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados